Poster: Utility of Intradermally Administered Botulinum Toxin In The Treatment of Macular Amyloidosis (For Professionals)
Poster: Utilty of Intradermally Administered Botulinum Toxin In The Treatment of Macular Amyloidosis (For Professionals)
Observation :
-male patient of 55 years of age, phototype IV
-followed-up for macular amyloidosis (histologically proven) for 4 years, located preesternally, in the interscapular and scapular areas.
-intense nocturnal pruritus (8 on a scale from 0 to 8).
-lesions and pruritus unresponsive to topical steroids, anti-H1 antihistaminics and to 30 treatment sessions of narrow-band UV phototherapy.
-2 weeks after intradermal injections of type A botulinum toxin (Botox) :
- quantity of 2.5 units of toxin spaced by 2cm.
- concentration of 25 unites per millilitre of physiologic serum.
- reduction of pruritus:
- from 8/10 to 4/10 in the presternal and interscapular areas.
- from 8/10 to 0/10 in the scapular area.
- Lasting: no recurrence after 6 months.
-Comment: no description of an improval in the clinical appearance of lesions.
Conclusion: symptomatic efficacy of the treatment of macular amyloidosis with botulinum toxin.
Declared conflicts of interest : non mentioned on the poster
Contributors:
Dr Christophe HSU – dermatologist. Geneva, Switzerland
Source of information (French): Poster (Dauendorffer JN et al.). Journées Dermatologiques de Paris 2009.
